S&P 500   3,959.13 (+0.64%)
DOW   33,718.76 (+0.36%)
QQQ   284.17 (+1.30%)
AAPL   142.88 (+1.38%)
MSFT   247.75 (+1.38%)
META   115.65 (+1.51%)
GOOGL   94.27 (-0.71%)
AMZN   90.63 (+2.45%)
TSLA   173.94 (-0.06%)
NVDA   171.23 (+6.22%)
NIO   13.41 (+6.60%)
BABA   94.06 (+6.49%)
AMD   70.34 (+0.29%)
T   19.08 (-1.14%)
MU   55.25 (+2.66%)
CGC   3.00 (-7.41%)
F   13.14 (+0.31%)
GE   83.32 (-1.98%)
DIS   92.54 (+0.42%)
AMC   6.12 (+1.16%)
PYPL   74.47 (+0.07%)
PFE   51.56 (+2.63%)
NFLX   309.75 (+0.43%)
S&P 500   3,959.13 (+0.64%)
DOW   33,718.76 (+0.36%)
QQQ   284.17 (+1.30%)
AAPL   142.88 (+1.38%)
MSFT   247.75 (+1.38%)
META   115.65 (+1.51%)
GOOGL   94.27 (-0.71%)
AMZN   90.63 (+2.45%)
TSLA   173.94 (-0.06%)
NVDA   171.23 (+6.22%)
NIO   13.41 (+6.60%)
BABA   94.06 (+6.49%)
AMD   70.34 (+0.29%)
T   19.08 (-1.14%)
MU   55.25 (+2.66%)
CGC   3.00 (-7.41%)
F   13.14 (+0.31%)
GE   83.32 (-1.98%)
DIS   92.54 (+0.42%)
AMC   6.12 (+1.16%)
PYPL   74.47 (+0.07%)
PFE   51.56 (+2.63%)
NFLX   309.75 (+0.43%)
S&P 500   3,959.13 (+0.64%)
DOW   33,718.76 (+0.36%)
QQQ   284.17 (+1.30%)
AAPL   142.88 (+1.38%)
MSFT   247.75 (+1.38%)
META   115.65 (+1.51%)
GOOGL   94.27 (-0.71%)
AMZN   90.63 (+2.45%)
TSLA   173.94 (-0.06%)
NVDA   171.23 (+6.22%)
NIO   13.41 (+6.60%)
BABA   94.06 (+6.49%)
AMD   70.34 (+0.29%)
T   19.08 (-1.14%)
MU   55.25 (+2.66%)
CGC   3.00 (-7.41%)
F   13.14 (+0.31%)
GE   83.32 (-1.98%)
DIS   92.54 (+0.42%)
AMC   6.12 (+1.16%)
PYPL   74.47 (+0.07%)
PFE   51.56 (+2.63%)
NFLX   309.75 (+0.43%)
S&P 500   3,959.13 (+0.64%)
DOW   33,718.76 (+0.36%)
QQQ   284.17 (+1.30%)
AAPL   142.88 (+1.38%)
MSFT   247.75 (+1.38%)
META   115.65 (+1.51%)
GOOGL   94.27 (-0.71%)
AMZN   90.63 (+2.45%)
TSLA   173.94 (-0.06%)
NVDA   171.23 (+6.22%)
NIO   13.41 (+6.60%)
BABA   94.06 (+6.49%)
AMD   70.34 (+0.29%)
T   19.08 (-1.14%)
MU   55.25 (+2.66%)
CGC   3.00 (-7.41%)
F   13.14 (+0.31%)
GE   83.32 (-1.98%)
DIS   92.54 (+0.42%)
AMC   6.12 (+1.16%)
PYPL   74.47 (+0.07%)
PFE   51.56 (+2.63%)
NFLX   309.75 (+0.43%)
NASDAQ:BPTS

Biophytis - BPTS Stock Forecast, Price & News

$0.40
0.00 (0.00%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.39
$0.43
50-Day Range
$0.35
$0.69
52-Week Range
$0.35
$5.91
Volume
18,554 shs
Average Volume
216,683 shs
Market Capitalization
$8.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Biophytis MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.76% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.25mentions of Biophytis in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.55) to ($1.63) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.55 out of 5 stars

BPTS stock logo

About Biophytis (NASDAQ:BPTS) Stock

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Receive BPTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biophytis and its competitors with MarketBeat's FREE daily newsletter.

BPTS Stock News Headlines

Biophytis S.A. (NASDAQ:BPTS) Short Interest Down 7.7% in November
Biophytis Announces Receipt of Nasdaq Notice
BPTS Biophytis S.A.
Biophytis S.A. ADR
BTCM, ANTE and CLNN among mid-day movers
See More Headlines
Receive BPTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biophytis and its competitors with MarketBeat's FREE daily newsletter.

BPTS Company Calendar

Today
12/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BPTS
Fax
N/A
Employees
24
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.56 per share

Miscellaneous

Free Float
19,325,000
Market Cap
$8.03 million
Optionable
Not Optionable
Beta
0.72

Key Executives

  • Mr. Stanislas Veillet Ph.D. (Age 57)
    Chairman & CEO
    Comp: $474.17k
  • Mr. Philippe J. Rousseau (Age 51)
    Chief Financial Officer
  • Mr. Waly Dioh (Age 53)
    Chief Operating Officer
  • Dr. Pierre J. Dilda (Age 52)
    Chief Scientific Officer
  • Dr. Rene Lafont (Age 76)
    Scientific Advisor & Member of Scientific Advisory Board
  • Mr. Benoit Canolle (Age 44)
    Chief Bus. Officer
  • Mr. Rob van Maanen FFPM (Age 52)
    M.B.A., M.D., Chief Medical Officer
  • Ms. _ Teylan
    Financial Controller













BPTS Stock - Frequently Asked Questions

Should I buy or sell Biophytis stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biophytis in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BPTS shares.
View BPTS analyst ratings
or view top-rated stocks.

How have BPTS shares performed in 2022?

Biophytis' stock was trading at $5.34 at the start of the year. Since then, BPTS shares have decreased by 92.5% and is now trading at $0.40.
View the best growth stocks for 2022 here
.

Are investors shorting Biophytis?

Biophytis saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 152,700 shares, a decline of 7.7% from the October 31st total of 165,400 shares. Based on an average trading volume of 198,300 shares, the days-to-cover ratio is currently 0.8 days.
View Biophytis' Short Interest
.

When did Biophytis IPO?

(BPTS) raised $20 million in an initial public offering (IPO) on Wednesday, February 10th 2021. The company issued 1,200,000 shares at $15.00-$18.00 per share. H.C. Wainwright acted as the underwriter for the IPO.

What is Biophytis' stock symbol?

Biophytis trades on the NASDAQ under the ticker symbol "BPTS."

How do I buy shares of Biophytis?

Shares of BPTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biophytis' stock price today?

One share of BPTS stock can currently be purchased for approximately $0.40.

How much money does Biophytis make?

Biophytis (NASDAQ:BPTS) has a market capitalization of $8.03 million.

How can I contact Biophytis?

Biophytis' mailing address is SORBONNE UNIVERSITY BC 9 BATIMENT A 4EME ETAGE 4 PLACE JUSSIEU, PARIS I0, 75252. The official website for the company is www.biophytis.com. The company can be reached via phone at 33-1-44-37-23-00.

This page (NASDAQ:BPTS) was last updated on 12/8/2022 by MarketBeat.com Staff